for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Novo Nordisk A/S

NOVOb.CO

Latest Trade

436.60DKK

Change

-3.10(-0.71%)

Volume

1,204,392

Today's Range

435.25

 - 

442.40

52 Week Range

312.00

 - 

456.30

As of on the Copenhagen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
439.70
Open
440.20
Volume
1,204,392
3M AVG Volume
63.51
Today's High
442.40
Today's Low
435.25
52 Week High
456.30
52 Week Low
312.00
Shares Out (MIL)
2,301.56
Market Cap (MIL)
791,365.40
Forward P/E
24.41
Dividend (Yield %)
1.91

Next Event

Q2 2020 Novo Nordisk A/S Earnings Release

Latest Developments

More

Novo Nordisk: Rybelsus Approved In Japan

Novo Nordisk Successfully Completes Am833 Phase 2 Trial And Phase 1 Combination Trial

Novo Nordisk: Semaglutide 2.4 Mg Shows Superior Weight Loss Versus Placebo In Phase 3 Trials

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.

Industry

Biotechnology & Drugs

Contact Info

Novo Alle

2880

Denmark

+45.44.448888

https://www.novonordisk.com/

Executive Leadership

Helge Lund

Independent Chairman of the Board

Lars Fruergaard Joergensen

President, Chief Executive Officer

Jeppe Christiansen

Vice Chairman of the Board

Karsten Munk Knudsen

Chief Financial Officer, Executive Vice President

Maziar Mike Doustdar

Executive Vice President, International Operations

Key Stats

2.56 mean rating - 27 analysts
Sell
Hold
Buy
Revenue (MM, DKK)

2017

111.6K

2018

111.8K

2019

122.0K

2020(E)

130.0K
EPS (DKK)

2017

15.390

2018

15.930

2019

16.380

2020(E)

17.974
Price To Earnings (TTM)
25.59
Price To Sales (TTM)
6.25
Price To Book (MRQ)
18.47
Price To Cash Flow (TTM)
17.17
Total Debt To Equity (MRQ)
7.56
LT Debt To Equity (MRQ)
5.27
Return on Investment (TTM)
68.22
Return on Equity (TTM)
34.18

Latest News

Latest News

BRIEF-Novo Nordisk: Rybelsus Approved In Japan

* REG-RYBELSUS® APPROVED IN JAPAN FOR THE TREATMENT OF TYPE 2 DIABETES

BRIEF-Novo Nordisk Successfully Completes Am833 Phase 2 Trial And Phase 1 Combination Trial

* REG-NOVO NORDISK SUCCESSFULLY COMPLETES AM833 PHASE 2 TRIAL AND PHASE 1 COMBINATION TRIAL WITH AM833 AND SEMAGLUTIDE IN OBESITY

BRIEF-Novo Nordisk: Semaglutide 2.4 Mg Shows Superior Weight Loss Versus Placebo In Phase 3 Trials

* REG-SEMAGLUTIDE 2.4 MG SHOWS SUPERIOR WEIGHT LOSS VERSUS PLACEBO IN THE PHASE 3 TRIALS STEP 2 AND STEP 3, THEREBY SUCCESSFULLY COMPLETING THE PROGRAMME

BRIEF-HBM Healthcare Investments: Novo Nordisk Buys Portfolio Company

* NOVO NORDISK ACQUIRES HBM PORTFOLIO COMPANY CORVIDIA THERAPEUTICS FOR UP TO USD 2.1 BILLION IN CASH Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Novo Nordisk expands into cardiovascular disease with $725 million deal

Novo Nordisk <NOVOb.CO> has agreed to buy AstraZeneca spin-off Corvidia Therapeutics for an initial $725 million as the world's largest diabetes drugmaker seeks to expand into cardiovascular disease treatments.

Novo Nordisk expands in cardiovascular disease with $725 mln deal

Novo Nordisk has agreed to buy AstraZeneca spin-off Corvidia Therapeutics for an initial $725 million as the world's largest diabetes drugmaker seeks to expand in cardiovascular disease.

BRIEF-Novo Nordisk To Acquire Corvidia Therapeutics

* NOVO NORDISK TO ACQUIRE CORVIDIA THERAPEUTICS AND EXPAND PRESENCE IN CARDIOVASCULAR DISEASE

BRIEF-Novo Nordisk Says Step 1 Trial Met Both Primary Endpoints

* REG- NOVO NORDISK REPORTS WEIGHT LOSS OF 14.9% (16.9% IF TAKEN AS INTENDED) IN STEP 1 TRIAL

BRIEF-Novo Nordisk: Maziar Mike Doustdar Sells 12,000 Shares In Co

* MAZIAR MIKE DOUSTDAR SELLS 12,000 SHARES IN CO WITH PRICE DKK 430.91 PER SHARE Source text for Eikon: Further company coverage: (Gdansk Newsroom)

Novo Nordisk's drug sales boosted by virus-related stockpiling

The world's top maker of diabetes drugs Novo Nordisk <NOVOb.CO> beat profit and sales forecasts in the first quarter and kept its full-year outlook as diabetics stocking up during the coronavirus pandemic led to a surge in demand for its medicines.

BRIEF-Novo Nordisk CFO Says Sales Of Its Obesity Drugs Impacted The Most By Coronavirus

* CEO SAYS DURING THE PERIOD OF SOCIAL DISTANCING FEWER NEW PATIENTS ARE EXPECTED TO INITIATE TREATMENT

BRIEF-Novo Nordisk Q1 EBIT Above Expectations At DKK 16,302 Mln

* NOVO NORDISK'S SALES INCREASED BY 16% IN DANISH KRONER AND BY 14% AT CONSTANT EXCHANGE RATES (CER) TO DKK 33.9 BILLION IN THE FIRST THREE MONTHS OF 2020

Novo Nordisk posts better-than-expected Q1 profit as stockpiling boosts sales

Denmark's Novo Nordisk posted a better-than-expected quarterly operating profit on Wednesday and kept its full-year outlook, as customers stocking up during the coronavirus pandemic boosted sales of its diabetes medicines.

BRIEF-Novo Nordisk Says Rybelsus approved for treatment of adults with type 2 diabetes in EU

* NOVO NORDISK - EUROPEAN COMMISSION GRANTED MARKETING AUTHORISATION FOR RYBELSUS FOR TREATMENT OF ADULTS WITH INSUFFICIENTLY CONTROLLED TYPE 2 DIABETES

BRIEF-Novo Nordisk Presents Results From Saxenda Trial

* SAID ON TUESDAY SAXENDA DEMONSTRATED IMPROVEMENTS IN BMI AND BODY WEIGHT IN ADOLESCENTS WITH OBESITY

BRIEF-NNIT Renews Operations Maintenance Agreement With Novo Nordisk

* REG-NNIT A/S: 6/2020 NNIT RENEWS OPERATIONS MAINTENANCE AGREEMENT WITH NOVO NORDISK

BRIEF-Novo Nordisk Will Not Start New Clinical Trials Due To Coronavirus -CEO

NOVO NORDISK CEO TOLD THE COMPANY'S ANNUAL GENERAL MEETING:

BRIEF-Novo Nordisk Pauses Clinical Trials Investigating Concizumab In Haemophilia A And B

* SAYS NOVO NORDISK PAUSES CLINICAL TRIALS INVESTIGATING CONCIZUMAB (ANTI-TFPI MAB) IN HAEMOPHILIA A AND B WITH OR WITHOUT INHIBITORS

BRIEF-Novo Nordisk Invests DKK 800 Million In Upgrading And Expanding Production Facilities In Kalundborg

* NOVO NORDISK INVESTS DKK 800 MILLION IN UPGRADING AND EXPANDING PRODUCTION FACILITIES IN KALUNDBORG

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up